Literature DB >> 6769666

Meal-dependent absorption of enteric-coated sodium valproate.

R H Levy, B Cenraud, P Loiseau, R Akbaraly, A Brachet-Liermain, M Guyot, R Gomeni, P L Morselli.   

Abstract

The effect of meals on valproic acid (VPA) absorption from an enteric coated (EC) formulation was investigated. In study I, six adult normal volunteers received a single 500 mg dose of sodium valproate in randomized treatments: fasting (A), with a meal (B) or 3 hours after a meal (C). There were significant differences between treatments in the latency period (Lp) defined as the time during which measured concentrations of VPA were less than 1 microgram/ml. Lp values for treatments A, B and C were: 1.67 +/- 1.25 hr, 6.75 +/- 3.98 hr and 7.63 +/- 3.15 hr respectively. In study II, six subjects (five from study I) received in a randomized fashion a 400 mg intravenous bolus dose of VPA and a 500 mg EC VPA tablet, 3 hours after a meal. The mean Lp value was 8.1 +/- 1.6 hr and the mean bioavailability was 100%. Clearance, volume of distribution and half-life values obtained after intravenous dosing were comparable to literature values. These results indicate that food intake delays but does not decrease the extent of absorption of VPA from an enteric coated formulation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769666     DOI: 10.1111/j.1528-1157.1980.tb04073.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  No effect of food intake on clobazam absorption.

Authors:  B Cenraud; M Guyot; R H Levy; A Brachet-Liermain; P L Morselli; T A Moreland; P Loiseau
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 3.  Mechanisms of anticonvulsant drug action. II. Drugs primarily used for absence epilepsy.

Authors:  C L Faingold; R A Browning
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

Review 4.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

6.  Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients.

Authors:  P Loiseau; B Cenraud; R H Levy; R Akbaraly; A Brachet-Liermain; M Guyot; P L Morselli
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 8.  Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.

Authors:  Manish Kumar Mishra; Samiksha Kukal; Priyanka Rani Paul; Shivangi Bora; Anju Singh; Shrikant Kukreti; Luciano Saso; Karthikeyan Muthusamy; Yasha Hasija; Ritushree Kukreti
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.